Sepracor Inc. hopes to complete at least one more major licensing deal in the next year after completing two licensing agreements in the past six months that have been worth a total of almost $30 million, according to Timothy Barberich, president and CEO. Sepracor's goal is to sign "one or two more of these significant deals" over the next 12 months, Barberich told BioCentury.

Sepracor is developing purer forms of popular drugs, either by substituting the active metabolite for the parent compound or by using a proprietary process to synthesize a single-isomer version of a drug that is a chiral compound. Chiral compounds contain a molecule that is the active ingredient, plus a molecule that is its mirror image and can be inactive or may create unwanted side effects.